Capture Hi-C identifies putative target genes at 33 breast cancer risk loci.

Joseph S Baxter[1]*, Olivia C Leavy[2,3]*, Nicola H Dryden[1]*, Sarah Maguire[1], Nichola Johnson[1], Vita Fedele[1], Nikiana Simigdala[1], Lesley-Ann Martin[1], Simon Andrews[4], Steven W Wingett[4], Ioannis Assiotis[5], Kerry Fenwick[5], Ritika Chauhan[1], Alistair G Rust[1], Nick Orr[1], Frank Dudbridge[2,3], Syed Haider[1#], Olivia Fletcher[1#].

[1]Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK

[2]Department of Non-communicable Disease Epidemiology, The London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK

[3]Department of Health Sciences, University of Leicester, Leicester, LE1 7RH, UK

[4]Bioinformatics Group, The Babraham Institute, Cambridge CB22 3AT, UK

[5]Tumour Profiling Unit, The Institute of Cancer Research, London, SW3 6JB, UK

* Contributed equally [#]Joint corresponding authors

Olivia Fletcher
The Institute of Cancer Research,
London, SW3 6JB, UK
Tel: +44 (0) 207 153 5177
Fax: +44 (0) 207 153 5340
E-mail: Olivia.Fletcher@icr.ac.uk

Syed Haider
The Institute of Cancer Research,
London, SW3 6JB, UK
Tel: +44 (0) 207 153 5338
Fax: +44 (0) 207 153 5340
E-mail: Syed.Haider@icr.ac.uk

Key words: Breast cancer; risk locus; target gene.

ABSTRACT

Genome-wide association studies (GWAS) have identified approximately 100 breast cancer risk loci. Translating these findings into a greater understanding of the mechanisms that influence disease risk requires identification of the genes or non-coding RNAs that mediate these associations. We used Capture Hi-C (CHi-C) to annotate 63 loci; we identified 110 putative target genes at 33 loci. All CHi-C interaction peaks can be viewed at bit.ly/CHiC-BC. To assess the support for these target genes in other data sources we tested for associations between levels of expression and SNP genotype (eQTLs), disease-specific survival (DSS), and compared them with somatically mutated cancer genes. 22 putative target genes were eQTLs, 32 were associated with DSS and 14 have been shown to be somatically mutated in breast, or other, cancers. Identifying the target genes at GWAS risk loci will lead to a greater understanding of the mechanisms that influence breast cancer risk and prognosis.

Genome-wide association studies (GWAS) coupled with large-scale replication and fine mapping studies have led to the identification of approximately 100 breast cancer risk loci. Breast cancer is a heterogeneous disease with two main subtypes defined by the presence (ER+) or absence (ER-) of the estrogen receptor. Approximately 80% of newly diagnosed breast cancers are ER+ although this proportion varies with age at diagnosis and ethnicity[1]. The majority of breast cancer GWAS risk loci have been identified on the basis of their association with overall breast cancer risk, or risk of ER+ disease[2]. Most of the risk single nucleotide polymorphisms (SNPs) map to non-protein-coding regions and are thought to influence transcriptional regulation[3,4]; many map to gene deserts with the nearest known protein-coding genes mapping several hundred kilobases (kb) away. Translating these findings into a greater understanding of the mechanisms that influence an individual woman's risk requires the identification of causal variants and the targets of these causal variants (i.e. genes or non-coding RNAs that mediate the associations observed in GWAS). Systematic approaches to the functional characterisation of cancer risk loci have been proposed[4,5]. These include fine mapping of potentially large genomic regions (defined as regions that include all SNPs correlated with the published SNP with an $r^2 \leq 0.2$), the analysis of SNP genotypes in relation to expression of nearby genes (eQTL) and the use of chromatin association methods (chromosome conformation capture (3C) and Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET)) of regulatory regions to determine the identities of target genes. To facilitate a high-throughput approach to the identification of target genes at GWAS risk loci we developed Capture Hi-C (CHi-C)[6]. This novel Hi-C protocol[7] allows high-throughput, high resolution analysis of physical interactions between regulatory elements and their target genes. We have used CHi-C previously, to characterise three breast cancer risk loci mapping to gene deserts at 2q35, 8q24.21 and 9q31.2[6]. Here we selected 63 established breast cancer risk loci (Supplementary Table 1); we identify CHi-C interaction peaks involving 110 putative target genes mapping to 33 loci and demonstrate long-range interaction peaks some of which span megabase (Mb) distances and involve adjacent risk loci. We carry out

eQTL analyses, analyses of disease specific survival (DSS) and compare our putative target genes with somatically mutated cancer genes to assess the orthogonal support for these putative target genes.

RESULTS

Generating CHi-C libraries representing 63 breast cancer GWAS risk loci

We generated CHi-C libraries in two ER+ breast cancer cell lines (T-47D, ZR-75-1), two ER- breast cancer cell lines (BT-20, MDA-MB-231), one "normal" breast epithelial cell line (Bre80-Q-TERT (Bre80)) and a control, non-breast lymphoblastoid cell line (GM06990) (Supplementary Figure 1). We defined an interaction peak as any pair of HindIII fragments for which the number of di-tags was significantly (FDR adjusted $P < 0.01$) greater than expected under a negative binomial model, taking into account both the distance between the HindIII fragments and the propensity of the bait fragment to form interactions (''interactability''; Methods). The number of di-tags that constituted an interaction peak depended on the distance between the interacting fragments and ranged from 5 to 14,151. We defined a locus as a single continuous capture region, annotated by at least one risk SNP (Methods).

Distribution of CHi-C interaction peaks across the 63 risk loci

The number of interaction peaks at each locus, in each cell line ranged from zero to 1,744 (Supplementary Table 2, Supplementary Figure 2), with two outliers (1,744 at 8q21.11-rs2943559 in ZR-75-1 and 1,007 at 8q24.21-rs13281615 in T-47D). There were 12 loci (19.0%) at which there were no interaction peaks in any of the cell lines we examined (Supplementary Table 2); these loci were excluded from further analyses. 46 (90.2%) of the 51 loci that we were able to analyse were identified on the basis of their association with overall breast cancer risk or risk of ER+ disease; the exceptions were 2p24.1-rs12710696, 5p15.33-rs10069690, 6q25.1-rs12662670, rs2046210, 16q12.2-

rs11075995 and 19p13.11-rs8170 which were associated with ER- and/or triple negative breast cancer (TNBC)[8-20].

We first tested for differences in the median number of interaction peaks across the six different cell lines according to ER status and cell type (breast/non-breast). The median number of interaction peaks per locus varied significantly between cell lines (Kruskal-Wallis test P = 0.0006; Table 1, Figure 1a). There were, on average, more statistically significant interaction peaks per locus in the ER+ breast cancer cell lines (T-47D, ZR-75-1) compared to the ER- breast cancer cell lines (BT-20, MDA-MB-231, Mann-Whitney test P = 0.0008) or the control lymphoblastoid cell line (GM06990, P = 0.002). There was, however, no difference between the number of interaction peaks per locus in the ER+ breast cancer cell lines and the normal mammary epithelial cell line (Bre80, P = 0.85; Table 1), consistent with Bre80 representing a progenitor cell population that gives rise to ER+ breast cancer cells. Similarly, the median distance between interacting fragments varied across cell lines (Kruskal-Wallis test $P < 1 \times 10^{-6}$; Table 1, Figure 1b) with a greater proportion of longest range interaction peaks (>2Mb) in the ER+ breast cancer cell lines compared to all other cell lines. In an analysis of 51 breast cancer cell lines, there was no evidence that luminal (ER+) cell lines carried more genome aberrations than basal (ER-) cell lines.[21] We cannot, however, exclude the possibility that rearrangements, gains and losses occur preferentially at ER+ risk loci in ER+ cell lines and this contributes to the higher proportion of long range interaction peaks we observe in the T-47D and ZR-75-1 breast cancer cell lines.

To gain further insight into the relationship between interaction peaks and cell type-specificity, we looked at the number of interaction peaks that were identical between two or more cell types. Of the 12,736 interaction peaks we identified 7,681 (60.3%) were present in a single cell line and 5,055 (39.7%) were present in multiple cell lines (FDR adjusted P < 0.01 Supplementary Table 3). The subset of interaction peaks that were present in at least two cell lines are provided as supplementary data (Supplementary Data). Excluding two loci with large outliers (i.e. 8q21.11-

rs2943559 and 8q24.21-rs13281615 at which there were 1,744 and 1,007 interaction peaks in T-47D and ZR-75-1, respectively; Supplementary Figure 2) the numbers were 4,924 (50.6%) and 4,805 (49.4%; Supplementary Table 3). We found a statistically significant excess of interaction peaks that were common to all four breast cancer cell lines (N = 62, P = 0.0003, Figure 1c) and all five breast cell lines (N = 53, P < 0.0001 Figure 1d). We also found an excess of interaction peaks that were exclusive to the lymphoblastoid cell line (N = 304, P < 0.0001) suggesting that at least a subset of interaction peaks show cell type specificity. Comparing the cell lines according to receptor type, the interaction peaks were marginally more similar within the two ER+ cell lines (Jaccard similarity coefficient = 0.18) and the two ER- cell lines (Jaccard similarity coefficient = 0.13) than between them (Figure 1e).

Representative examples of loci that demonstrated cell type-specific activity are shown in Figure 2. At several of the ER+ risk loci, including the 10q26.13-rs2981579 (*FGFR2*) and 14q13.3-rs2236007 (*PAX9*) risk loci, we observed interaction peaks that were restricted to the two ER+ breast cancer cell lines and the normal breast epithelial cell line (Figures 2a and c). In both these examples, the transcription start site (TSS) of the target gene maps within the capture region and forms interaction peaks with specific HindIII fragments that map several hundred kb from the capture region. These distal fragments colocalise with DNase I hypersensitive sites, CTCF, FOXA1, GATA3 and/or ERα binding sites in T-47D cells and in both of these examples the orientation of the CTCF binding sites is towards the captured locus (Figures 2b, d and e)[22].

There were, however, many exceptions to the pattern of ER+ risk loci forming interaction peaks in the ER+ breast cancer cell lines and Bre80s. The 11p15.5-rs3817198 risk locus, which is associated with ER+ breast cancer forms multiple interaction peaks in the ER- breast cancer cell lines, but not in the ER+ breast cancer cell lines or in Bre80 (Figure 3a, Supplementary Table 2) and the 6q25.1-rs2046210 (*ESR1*) locus which has been shown to be preferentially associated with ER- breast cancer[20,23] forms interaction peaks in the ER+ but not the ER- breast cancer cell lines (Figure 3b, Supplementary Table 2).

Defining putative target genes

We defined putative target genes as genes that mapped within, or *in cis* (≤ 5Mb) to, a captured region and for which the TSS mapped to an interacting fragment in at least two cell lines (Methods). On this basis, we were able to assign 110 putative target genes to 33 (64.7%) of the 51 loci (Table 2, Supplementary Table 4); 94 were protein coding and 16 were non-coding RNAs. The number of genes per locus, for these 33 loci ranged from one (13 loci) to 19 (11q13.1-rs3903072 locus) with a median of two. The distance between the published risk SNP and the TSS of the CHi-C target gene ranged from 1 kb (*KCNN4*) to more than 4 Mb (3p26.1-rs6762644 with *CAV3, RAD18* and *SETD5*; 11q13.1-rs3903072 with *FADD*) with a median of 135 kb (individual distances between risk SNPs and CHi-C target genes are given in Supplementary Table 5). Amongst our 51 informative risk loci there were 24 (at 12 chromosomal regions) that mapped within five Mb of another locus (Supplementary Table 1). We observed interaction peaks between adjacent loci at eight of these chromosomal regions and were able to potentially assign target genes to three additional loci on the basis of interaction peaks with the adjacent locus (Table 2). These loci were 8q21.11-rs6472903 (*HNF4G* and *PEX2*), 9q31.2-rs10759243 (*KLF4*) and 14q24.1-rs999737 (*ZFP36L1*); a representative example, showing interaction peaks within and between adjacent loci at 11q13, is shown in Figure 4. For the interaction peaks with the longest-range gene targets (3p26.1-rs6762644: *CAV3*, *LINC00312*, *LMCD1, c3orf32*, *RAD18*, *SETD5*, 4q24-rs9790517: *CENPE*, 8q24.21-rs13281615: *CCDC26*, 11q13.1-rs3903072: *CCND1*, *FADD*) we aligned our data with topologically associated domains (TADs) generated in Human Mammary Epithelial Cells (HMEC)[24]. At each of these loci we observed interaction peaks between captured fragments and target gene(s) mapping within the same TAD but also, less frequently, with target gene(s) mapping to a different TAD (Supplementary Figure 3).

To determine whether the target genes selected using a CHi-C approach differ from those selected simply on the basis of proximity to the GWAS risk SNP ("nearest gene approach") we compared the two approaches directly. At 15 of the 51 loci included in our analysis, we were unable to assign

target genes (i.e. there were no TSS directly or indirectly involved in statistically significant interaction peaks). Of the 36 loci at which we were able to assign at least one target gene directly (N=33) or indirectly (N=3) there were 24 at which the nearest gene was either the only CHi-C target gene (N=9; Table 2) or one of several CHi-C target genes (N=15; Table 2). There were, however, 12 loci at which our data implicated genes other than the nearest gene; these loci included 13q13.1-rs11571833 (CHi-C gene: *PDSB5*, nearest gene: *BRCA2*), 14q24.1-rs2588809 and rs999737 (CHi-C gene: *ZFP36L1*, nearest gene: *RAD51B*) and 16q12.2-rs17817449 and rs11075995 (CHi-C genes: *CRNDE, IRX5, IRX3, LOC100996*, nearest gene: *FTO*).

CHi-C target genes and eQTL analyses

To assess the likelihood of our putative target genes having a causal role in breast cancer aetiology, we first carried out eQTL analyses using the published risk SNPs (or a close proxy, $r^2 > 0.8$) and RNA-Seq data from the Cancer Genome Atlas[25] (TCGA) adjusted for matched DNA methylation and somatic copy-number alterations. Many of risk loci we included have been shown to be associated with breast cancer risk overall, albeit with evidence that the association may differ in magnitude between ER+ and ER- cancers for some[26]. Accordingly, we carried out eQTL analyses for all cancers combined (N = 547) and then stratified by ER status (ER+ N = 415, ER- N = 95, ER unknown N = 37). There were 9 loci (26 protein coding genes) at which there were no suitable proxies, and levels of expression of 18 of our putative target genes (*KRTPA5-5*, *KRTAP5-6* and 16 non-coding RNAs) were too low for analysis. eQTL analysis of the remaining 26 loci (69 protein coding genes) identified 22 SNP-gene combinations that were nominally significant ($P < 0.05$) in all, ER+ or ER- breast cancers (Supplementary Table 6), nine of which remained significant after taking account of multiple testing (FDR adjusted $P < 0.1$,Table 3). Comparing these eQTLs with “nearest genes”, three were nearest genes and six were not. Including all nearest genes (regardless of whether they were also a CHi-C target gene) in our eQTL analysis we found two additional SNP-gene combinations that were not captured by our CHi-C analysis; rs4808801 was associated with levels of expression of *ELL* in all

cancers and ER+ cancers and rs8170 was associated with levels of expression of *ANKLE* in all cancers (FDR adjusted P < 0.1).

Several of the CHi-C target gene eQTLs were consistent with previous reports including *IGFBP5* at 2q35-rs13387042[6,27], *COX11* at 17q22-rs6504950[28] and *LRRC25* at 19p13.11-rs4808801[29]. Novel eQTLs included genes that mapped within the capture region, proximal to the reported risk SNP such as *CDCA7* at 2q31.1-rs1550623, *SSBP4* at 19p13.11-rs4808801 and *MRPL34* at 19p13.11-rs8170 as well as genes that mapped several hundred kb from the reported SNP including *IRX3* at 16q12.2-rs17817449 and *ZFP36L1* at 14q24.1-rs2588809. At 11q13.1-rs3903072, eQTL analyses support multiple putative target genes of which *SNX32*, *CTSW* and *CFL1* map within the capture region but, intriguingly, *FADD* and *CCND1* map at a distance of approximately 4Mb from rs39030702 (Figure 4). Both *FADD* and *CCND1* map to a region of chromosome 11 that is frequently subject to amplifications and copy number gains in breast cancer (*FADD* and *CCND1* map to regions of copy-number gain in 20 – 30% of Metabric[30] and TCGA samples), raising the concern that this long range eQTL association might be influenced by these samples. Excluding samples with genomic copy-number gains from the analysis, however, strengthened the association between 11q13.1-rs3903072 and *FADD* (all samples P_{ER+} = 0.01, excluding 119 samples with copy-number gains P_{ER+} = 0.004; Figure 5a and 5c), but not *CCND1* (all samples P_{ER+} = 0.04, excluding 130 samples P_{ER+} = 0.05: Supplementary Figure 4).

CHi-C target genes and disease-specific survival (DSS)

To our knowledge, only one of the risk SNPs we included has been associated with disease prognosis (16q12.1-rs3803662 and *TOX3*[31]); this may reflect a fundamental difference between the genetics of predisposition and prognosis or a relative lack of power for observational studies of outcome in which detailed information on treatment is generally lacking. As any individual regulatory variant may only explain a small proportion of the total variance in gene expression, however, we looked directly for an association between levels of expression of our putative target genes and patient

211 outcome in the Metabric breast cancer cohort[30]. Given the profound effect of ER status on outcome,
212 we performed survival analyses on ER+ and ER- subpopulations separately. Of the 97 putative target
213 genes (94 protein coding, three non-coding RNAs) for which levels of expression were available, 32
214 (33%) were associated with disease-specific survival (DSS) in individuals with ER+ disease; none was
215 associated with DSS in ER- disease (FDR adjusted $P < 0.1$; Supplementary Table 7). Comparing these
216 32 genes with those for which we found eQTL associations in ER+ cancers (nominal $P < 0.05$) there
217 were six that were common to both groups (*CFL1, FADD, MRPL34, IGFBP5, IRX3, ZFP36L1*). In
218 addition, there was a highly significant association between levels of expression of *CDCA7* and DSS (P
219 $= 1.22 \times 10^{-8}$), which maps just 7 kb from the reported 2q31.1 risk SNP (rs1550623) but while there
220 was a robust eQTL association between rs1550623 and *CDCA7* in all cancers (nominal $P = 0.007$, FDR
221 adjusted $P = 0.09$) there was no association in ER+ cancers alone (both $P > 0.1$). We also observed
222 highly significant associations (FDR adjusted $P < 0.005$) for five genes that were excluded from eQTL
223 analysis due to a lack of suitable tag SNP (*CENPE* at 4q24, *TPCN2* and *ORAOV1* at 11q13.3, *PDS5B* at
224 13q13.1 and *SLC4A7* at 3p24.1: Supplementary Figure 5)

225 <u>CHi-C target genes and somatic mutations in cancer genes</u>

226 Finally, we compared our CHi-C putative target genes with the list of 727 cancer genes compiled by
227 Nik-Zainal and colleagues in their analysis of whole genome sequences of 560 breast cancers[32]. The
228 94 protein-coding CHi-C target genes are highly enriched for these cancer genes (14 observed,
229 Hypergeometric $P = 2.02 \times 10^{-6}$) and include well-documented cancer genes (*CCND1, CDKN2A,*
230 *CDKN2B, MYC, MAP3K1, ESR1* and *FGFR2*) as well as relatively uncharacterised examples (*TET2,*
231 *KLF4, MLLT10*, *FADD, TBX3, PAX9* and *ZFP36L1*).

232 Combining the somatic mutation data with the eQTL and DSS analyses, there were 48 CHi-C target
233 genes mapping to 32 loci for which there was orthogonal support from at least one additional source
234 and six genes mapping to six loci for which there was support from at least two additional sources
235 (Table 4). For four of these, *CDCA7, FADD, ZFP36L1* and *MRPL34,* levels of expression were

associated with both SNP genotype and DSS (Table 4) and we were able to assess whether high (or low) levels of expression were similarly associated with risk and poor outcome. For *FADD* the associations are inconsistent; the rare allele of 11q13.1-rs3903072 is associated with higher levels of expression (Figure 5a) and lower risk[26], but higher levels of expression are associated with poor outcome (Figure 5b). In addition, the strong influence of copy number gains on levels of expression of *FADD* confounds both eQTL and DSS analyses with opposite effects; excluding 119 ER+ cancers with copy-number gains strengthens the eQTL association in TCGA (Figure 5c), excluding 345 such samples from the analysis of outcome in Metabric abrogates the association with DSS (Figure 5d) suggesting that samples with copy-number gains at this region may have a poor outcome that is not directly related to levels of expression of *FADD*. Similarly, for *CDCA7* the associations are inconsistent. The risk allele of rs1550623 is the common allele[26]; the common allele is associated with lower levels of *CDCA7* expression (Figure 5e) but lower levels of expression of *CDCA7* are associated with a better prognosis (Figure 5f). However, for both 14q24.1-rs2588809 (*ZFP36L1*) and 19p13.1-rs8170 (*MRPL34*) the rare alleles are associated with lower levels of expression (Figure 5g and 5i) and higher risk[26] ; lower levels of expression are also associated with a poor outcome (Figure 5h and 5j) consistent with these genes acting as tumour supressors influencing both predisposition and outcome similarly.

DISCUSSION

The purpose of this analysis was to identify target genes at 63 breast cancer GWAS risk loci using an unbiased, high resolution chromosome association method, CHi-C and evaluate this method in comparison to a simple “nearest gene” approach. We were able to assign 110 putative target genes to 33 loci; 94 were protein coding and 16 were non-coding RNAs. We used three publicly available data sources to assess support for our CHi-C target genes as having a causal role in breast cancer aetiology. In eQTL analyses we identified 22 SNP-gene combinations that were nominally significant ($P < 0.05$) in all, ER+ or ER- breast cancers in TCGA. DSS analyses of ER+ breast cancers in the

Metabric cohort supported 32 CHi-C target genes (FDR adjusted P < 0.1) and 14 were listed in 727 cancer genes compiled by Nik-Zainal and colleagues. In all data sources combined there was support for 48 CHi-C target genes mapping to 32 loci from at least one additional source and there was support for six genes mapping to six loci from at least two additional sources. These data suggest that a substantial proportion of the CHi-C putative target genes are likely to influence breast cancer risk and warrant further investigation.

However, amongst the 63 risk loci that we investigated there were 12 at which we detected no interaction peaks at all. This may, in part, be a consequence of our methodology as 3C-based techniques are not considered reliable for detecting interactions over distances of less than 10 kb [33]; at three of these 12 loci (4q34.1-rs6828523 (*ADAM29*), 10q21.2-rs10995190 (*ZNF365*) and 16q12.1-rs3803662 (*TOX3*) the TSS of a nominated target gene mapped within 10kb of the reported SNP. Similarly, for the 15 loci at which the interaction peaks we detected did not include direct, or indirect, interactions with the promoter of a RefSeq gene, there were four at which the TSS of the proposed target gene mapped within 10 kb (6p25.3-rs11242675 (*FOXQ1*), 22q12.1-rs17879961 (*CHEK2*)) or 20kb (5p15.33-rs10069690 (*TERT*), 22q12.1-rs132390 (*EMID1*)) of the reported SNP (Supplementary Table 2). In any analysis, there is a trade-off between type I and type II errors. By using a rigorous threshold (FDR adjusted P < 0.01) for calling an interaction peak "significant" we will have minimised false positives but we may also have missed potentially important low frequency interactions. Finally, we may have missed important target genes by using a restricted set of cell lines that will only capture interaction peaks between regulatory elements and genes that are expressed in breast epithelial cells. At the other extreme, there were several loci mapping to gene-rich regions (particularly 11q13 and 19p13), at which we observed interaction peaks with multiple putative target genes some of which mapped to the same HindIII restriction fragment as another target gene (Table 2). Reducing the size of the average restriction fragment, by using an enzyme that cuts more frequently would provide greater resolution, but it is clear that CHi-C cannot resolve

interaction peaks at the TSS of putative target genes that map within a few hundred base pairs of each other.

The other metrics that are frequently used for defining putative target genes are nearest gene, or nearest plausible gene, and eQTL analyses. While in many cases our analyses support the nearest gene or the nearest plausible gene the limitations to this approach are obvious; there are many examples of long range interactions between regulatory elements and target genes that bypass more proximal putative target genes[34-36]. Comparing CHi-C with a nearest-gene metric for assigning putative target genes to risk loci, our data were informative at 36 (57%) of the 63 loci we selected for analysis and at 27 (43%) our data implicated genes in addition to, or other than, the nearest gene. Notably, our data implicates several protein coding genes and non-coding RNAs that map at distances of more than 1Mb from the published risk SNP (ie outside the limit of many eQTL analyses). While the presence of these long range interactions may inform future follow up studies, they do not exclude effects that are more local to the risk loci. In their functional annotation of the human genome, the ENCODE consortium estimated that the average number of TSSs that interact with any given distal element is 2.5[37] and regulatory variants that map to such elements may influence absolute or relative levels of expression of multiple genes. Of the six genes for which there was support from at least two additional data sources, neither *ZFP36L1* (which maps 600 kb from rs2588809) nor *FADD* (mapping 4.5 Mb from rs3903072) would have been selected by a nearest gene metric supporting the use of CHi-C as a means of identifying putative target genes that map several hundred kb or even Mb from the risk locus.

eQTL analyses provide an intuitive approach to the process of identifying putative target genes. However, implicit in eQTL analyses of breast cancer or normal breast tissue is an assumption of a model in which a breast cancer GWAS locus influences risk by altering steady-state expression of a gene that is transcribed in normal or malignant breast tissue; this may not be true for a substantial minority of loci. For this reason, a CHi-C based approach which detects “permissive” interaction

peaks (as well as "instructive" interaction peaks)[33,38] may have benefits over an eQTL based approach by allowing the identification of putative target genes that are poised for expression at a particular stage of differentiation or in response to external stimuli such as hormones or DNA damage.

The variants detected by GWAS are common variants with small effects (ORs are typically < 1.2) and any individual risk SNP will usually only explain a small proportion of variance in levels of expression of a target gene. For example, the association between 11q13.1-rs3903072 and *FADD* is weak in all ER+ cancers (nominal P = 0.01); excluding ER+ cancers with copy number gains reduces the variance in levels of expression of *FADD* and increases the proportion of variance explained by rs3903072 (nominal P = 0.004). Given the small effects of individual variants, eQTL approaches based on current data sets of a few hundred samples lack power. To limit the penalty for multiple testing, most eQTL analyses are restricted to genes within a 1Mb window of the risk SNP or a proposed causal variant. In our eQTL analysis we used our CHi-C results to restrict our gene set to 69 protein-coding genes. Despite this our eQTL analysis probably lacked power, particularly for the stratified analyses where there were just four ER+ eQTLs and no ER- eQTLs that were significant after taking account of multiple testing. Indeed *IGFBP5*, *KLF4*, *CFL1*, *CCND1* and *IRX3* are all fairly compelling putative target genes with nominal associations for which the adjusted eQTL P-values were non-significant (all nominal $P_{ER+} < 0.05$, all FDR adjusted $P_{ER+} > 0.1$).

For several of the risk loci that we included, functional annotation studies have been previously reported on a locus-by-locus basis [27,28,39-51] and target genes have been inferred by a combination of proximity, eQTL analysis and testing for looping interactions on a candidate basis using 3C. Our CHi-C targets are consistent with many of these[27,28,43,46,47] but may implicate *CENPE* in addition to *TET2* at 4q24[40] and *MRPL34* in addition to *ABHD8* or *ANKLE1* at 19p13.1[51]. The other notable feature of our data is the frequency with which we observed interaction peaks between adjacent loci several of which map megabase distances apart. This feature, and our observation of an eQTL between

rs3903072 and both *CFL1* and *FADD* which map 4.5 Mb apart, suggests that the number of target genes may be less than the number of reported risk loci albeit with, potentially, multiple co-regulated target genes at some loci.

Overall it is difficult to evaluate our list of putative target genes when fully understanding the mechanisms by which a given gene influences cancer risk are often complex and require many years' work. It seems likely, however, that the first stage of this process will be short-listing candidates for follow up studies. On that basis, we would argue that a high-throughput CHi-C analysis can contribute to on-going efforts to functionally annotate GWAS risk loci and that CHi-C target genes that are supported by additional data sources are strong candidates for in depth functional follow up studies.

METHODS

Target Enrichment Array Design

74 SNPs mapping to 68 GWAS risk loci were selected based on all available published GWAS and replication studies as of 31/01/2015. Capture regions were defined as the region that included all SNPs that were correlated ($r^2 \geq 0.2$) with the published SNP based on 1000 Genomes pilot data (http://www.1000genomes.org/; Supplementary Table 1). Biotinylated 120-mer RNA baits were designed to target both ends of the HindIII restriction fragments that mapped within these capture regions using Agilent eArray software (Agilent, Santa Clara, CA, USA), using 2x tiling, moderately stringent repeat masking and maximum performance boosting options.

Cell culture and formaldehyde crosslinking

T-47D, ZR-75-1, BT-20 and MDA-MB-231 cell lines were obtained from ATCC (Middlesex, UK), GM06990 cells were supplied by Coriell Cell Repositories (Coriell Institute for Medical Research, New Jersey, USA). Normal Bre80 TERT-immortalised mammary epithelial cells Bre80-Q-TERT (Bre80), were kindly provided by Prof Georgia Chenevix-Trench (Queensland Institute of Medical Research, Brisbane, Queensland, Australia). Cell lines were authenticated using STR genotyping and were regularly tested for mycoplasma contamination. Bre80 cells were grown in DMEM/F12 with phenol red (Gibco, Life Technologies) supplemented with 5% horse serum, 10µg/ml insulin, 0.5µg/ml hydrocortizone, 20ng/ml epidermal growth factor, 100ng/ml cholera toxin, 50U/ml penicillin and 50µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA). T-47D and ZR-75-1 were grown in RPMI 1640 (Gibco, Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 50U/ml penicillin, 50µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and, for T-47D, 10µg/ml insulin (Sigma-Aldrich, St. Louis, MO, USA). BT-20 cells were grown in EMEM (ATCC, Middlesex, UK) supplemented with 10% FBS, 50U/ml penicillin, 50µg/ml streptomycin. MDA-MB-231 cells were grown in DMEM supplemented with 10% FBS, 50U/ml penicillin, 50µg/ml streptomycin and

GM06990 cells were grown in RPMI 1640 supplemented with 15% FBS, 50U/ml penicillin, 50µg/ml streptomycin and 2mM L-Glutamine. Formaldehyde crosslinking of 20 million cells was performed as described by Belton and colleagues [52] by substituting standard culture media with FBS-free media containing 2% formaldehyde for 5 minutes at room temperature. Crosslinking was quenched by addition of glycine to a final concentration of 150mM. Adherent T-47D, ZR-75-1, BT-20, MDA-MB-231 and Bre80 cells were scraped off the culture flask after crosslinking, non-adherent (GM06990) cells were transferred directly to a falcon tube. Cells were washed with cold PBS, snap-frozen in liquid nitrogen and stored at -80°C before preparation of the Hi-C library.

Hi-C library generation

Each cross-linked cell aliquot (~20 million cells) was re-suspended in 50ml of permeabilisation buffer (10mM Tris-HCl pH8, 10mM NaCl, 0.2% IGEPAL CA-630 (Sigma-Aldrich, St. Louis, MO, USA), supplemented with complete mini EDTA-free tablets (Roche, Basel, Switzerland) and incubated on ice for 30 minutes with occasional mixing. T-47D, ZR-75-1 and GM06990 cells were lysed using 10 strokes of a dounce homogeniser. BT-20, MDA-MB-231 and Bre80 cells were lysed by incubating with trypsin (0.25%, Sigma-Aldrich, St. Louis, MO, USA) at 37°C for 5 minutes. Trypsin was inactivated by addition of 500µl FBS. Permeabilised cells were centrifuged for 6 minutes at 600g and washed three times in 1ml 1.3 x NEBuffer 2 (New England Biolabs, Ipswich, MA, USA). Nuclei were resuspended and chromatin digestion and Hi-C library preparation were carried out as described by van Berkum and colleagues [7] with the following modifications: (i) cells were split into three microcentrifuge tubes instead of five (ii) restriction fragment overhangs were filled in with biotinylated dATP instead of biotinylated dCTP (iii) dGTP was not added to the reaction mixture for the removal of biotinylated dATP from unligated ends (iv) an agarose gel size selection step was not included, and (v) after PCR amplification (5-8 cycles) of the Hi-C library-bound streptavidin beads the PCR product was pooled and subjected to target enrichment (below) before paired end sequencing.

Target enrichment

Target enrichment was performed based on the SureSelect protocol (Agilent, Santa Clara, CA, USA) but incorporating the following modifications: (i) Biotinylated Hi-C ditags bound to streptavidin-beads were amplified pre-hybridization directly from beads using 24 parallel 25µl PCR reactions with five to eight cycles using Q5 High-Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA, USA) and pre-hybridization PCR primers: ACACTCTTTCCCTACACGACGCTCTTCCGATC*T and CTCGGCATTCCTGCTGAACCGCTCTTCCGATC*T. PCR products were pooled and purified using Agencourt Ampure XP beads (Beckman Coulter, Brea, CA, USA) to yield approximately 750-1300ng total DNA. 750ng of library DNA was dried using a speedvac concentrator then resuspended in 3.4µl of water. (ii) Enriched fragments were amplified post-hybridization again directly from the streptavidin beads, using 18 parallel 25µl reactions of five to eight cycles of PCR. PCR products were again pooled and purified using Agencourt Ampure XP beads (Beckman Coulter, Brea, CA, USA). Post-hybridization PCR primers to the paired end adaptors were as described in Belton and colleagues [52]

Paired-end next generation sequencing (NGS), mapping and filtering

12 target enriched Hi-C libraries (two biological replicates for each of six cell lines) were prepared. Eight of the libraries (all at concentrations >2,500 pM) were sequenced on single flow cell lanes on an Illumina HiSeq2000 (Illumina, San Diego, CA, USA) generating 76bp paired-end reads. The other four libraries, which were at lower concentrations (330-630 pM), were sequenced on two flow cell lanes each. Casava software (v1.8, Illumina) was used to make base calls; reads failing the Illumina chastity filter were removed before further analysis. Sequences were output in fastq format before mapping against the human reference genome (GRCh37/hg19) generating between 86 and 153 million di-tags with both ends uniquely mapped to the reference genome. Filtering to remove experimental artefacts was carried out using the publicly available Hi-C User Pipeline (HiCUP). Full details of this pipeline are available from Babraham Bioinformatics (http://www.bioinformatics.babraham.ac.uk/). In addition to the standard pipeline, off-target di-

tags (defined as di-tags where neither end mapped to one of the capture regions) were removed from the final processed data sets. After excluding invalid pairs [52,53], PCR duplicates, and off-target di-tags, the number of valid di-tags ranged from 24 to 71 million. Full details of the number and proportion of excluded di-tags are given in Supplementary Table 8.

Analysis of Hi-C interaction peaks

The power of our analysis to detect significant interaction peaks depends on the read density, which in turn depends on the size of the bin or unit of analysis. Given that our purpose was to identify individual target genes, we restricted the analysis to a high resolution (single HindIII fragment) analysis of valid di-tags generated by ligations between a captured fragment and (i) another captured fragment in *cis* or (ii) a non-captured fragment in *cis*, mapping within five Mb[6]. We carried out separate analyses for each type of ligation on the basis that the statistical properties of ligations where both ends of the di-tag have been captured (type (i)) will differ from those where just one end has been captured (type (ii)).

To assess the reproducibility of our libraries we calculated Spearman's ρ for each possible combination of HindIII fragments, for each type of analysis ((i) and (ii)) using the two biological replicate libraries for each of the six cell lines. We excluded combinations of HindIII fragments for which there were zero read pairs in both libraries and stratified our analysis on the distance between the two HindIII fragments (0 – 500 kb, 500 kb – 1 Mb, 1 Mb – 1.5 Mb, > 1.5 Mb). The correlation between duplicates was strongest when both fragments were captured and mapped within 500 kb of each other (ρ = 0.78 to ρ = 0.92). For fragments separated by distances of > 1Mb (where most of the raw di-tags represent "noise") there was weak or no correlation between replicates (all $\rho < 0.4$); for fragments separated by 500 kb to 1 Mb correlation was moderate (ρ = 0.53 to ρ = 0.77 when both fragments were captured, and ρ = 0.33 to ρ = 0.59 when just one fragment was captured; Supplementary Figures 6 and 7).

There were eight loci annotated by 10 SNPs (5p15.33-rs10069690, 5p15.33-rs7726159 and rs2736108, 11q13.3-rs554219 and rs78540526, 11q13.3-rs75915166, 16q12.2-rs17817449, 16q12.2-rs11075995, 19p13.1-rs8170, 19p13.1-rs2363956) where the capture regions were too close for us to analyse separately. Accordingly we collapsed these eight regions into four regions. There was one region at 10q23.1-rs7071985 (82909977-83064943) that failed to generate high numbers of reads in any of the cell lines we assayed. After excluding this region and combining eight regions into four, there were 63 separate loci for analysis (Supplementary Table 1). On our arrays, there were also 1,254 captured HindIII fragments that did not map to known breast cancer risk loci and were not considered further in this study. Three of these fragments comprising the *GSTP1* promoter, mapped within 5Mb of the 11q13.1-rs3903072 capture region and formed interaction peaks with this capture region. For clarity these interaction peaks are excluded from Figure 4. For the 63 risk loci we generated data sets that comprised all di-tags in both categories (type (i) and (ii)) using the SeqMonk mapped sequence analysis tool (*www.bioinformatics.babraham.ac.uk/projects/seqmonk/*). Where a captured region mapped within five Mb of another captured region we considered HindIII fragments mapping to these two regions as part of a "within capture" (type (i)) analysis.

In common with other "C"-based techniques, our Capture Hi-C methodology includes several steps that will show local differences in efficiency thereby introducing biases in the detection of interaction peaks[35]. To correct for these biases, we used a modification of the procedure described by Sanyal and colleagues[6,35]. Briefly, our method assumes that some of our captured fragments "fail" and we exclude these; we then use a truncated negative binomial model, which takes account of both the large number of zero counts in the data and allows for overdispersion, to model all ligations for which one end maps an unexcluded captured fragment. R-scripts are available on request. In detail, on the assumption that the majority of *trans* ligations represent random events, we calculated the total number of *trans* ligations (N_T) made by each of the captured HindIII fragments as a measure of the fragment's "interactability", its propensity to interact with other fragments. The interactability had a bimodal distribution which we assumed to arise from two

components corresponding to low numbers of counts, which we regarded as stochastic noise, and higher numbers of counts, which we regarded as genuine signal. For each cell line and biological replicate a truncated negative binomial distribution, based on the number of di-tags, was fitted to the higher component. By visually inspecting the histogram, it was apparent that the truncation point varied between each cell line and biological replicate. Both the histograms and individual truncation points were used to define an individual threshold, this being the 5% quantile point of the corresponding non-truncated distribution, for each cell line and replicate. All fragments with a total number of trans di-tags below the corresponding threshold value were regarded as noise and were filtered out. This resulted in excluding between 8.6% and 30.0% of the fragments with the lowest number of *trans* ligations (di-tags). We fitted negative binomial regression models to the filtered data sets, combining data from the two biological replicates for each cell line. We corrected for experimental biases due to differing interactability of fragments by including as a covariate the $\log_e$ of the total number of *trans* ligations ($\ln(N_T)$) for each captured fragment from each biological replicate; for *cis* ligations within the capture regions we also included a term for interaction products of $\ln(N_T)$ for each of the two ligated fragments in each biological replicate. We corrected for distance between the ligated fragments by including as a covariate the $\log_e$ of the distance between the mid-points of the two fragments ($\ln(D)$); to approximate local smoothing we fitted the data in bins each of which contained 1 percentile of the distance range. P-values were obtained by comparing the observed counts to the fitted distributions. For each capture region in each cell line, we controlled the false discovery rate using the method of Benjamini & Hochberg[54]. Supplementary Figures 8 and 9 show raw read counts aligned to the reported interaction peaks in two libraries ((i) T-47D and (ii) MDA-MB-231 at the 10q26.13-rs2981579 locus (see Figure 2a) and the 11p15.5-rs3817198 locus (see Figure 3a).

Comparison of interaction peaks between cell lines

Non-parametric equality tests (Mann-Whitney for two samples, Kruskal-Wallis for multiple samples) were used to test for a difference in the median number of interaction peaks per locus and the median distance between interacting fragments, across cell lines. We tested the probability of an excess of shared interaction peaks among breast cancer cell lines and all breast-specific cell lines using a random sampling (10,000 permutations) and we estimated the similarity according to receptor status (ER+/ER-) for the breast cancer cell lines using the Jaccard similarity coefficient.

Allocating putative target genes and nearest genes

To define a set of putative target genes, we identified all catalogued RefSeq genes (GRCh37/hg19), mapping within, or *in cis* (≤ 5Mb) to a captured region. From these we selected the subset for which the transcription start-site (TSS) mapped to one end of an interaction peak (an interacting fragment). Given that cancer cell lines are aneuploid, with multiple rearrangements and regions of loss or gain, we further required that the TSS mapped to an interacting fragment in at least two cell lines. For SNPs that mapped to a RefSeq gene (UTR, exon or intron), this gene was considered to be the nearest gene (Table 2). For intergenic SNPs, the nearest gene was determined on the basis of the nearest RefSeq catalogued TSS. Where the nearest catalogued TSS was for a non-coding RNA, this non-coding RNA is listed along with the nearest protein-coding gene (Table 2).

Aligning CHi-C data with TADs.

In order to align CHi-C data with TADs, we accessed Hi-C data generated in HMECs[24] through the 3D genome browser (http://promoter.bx.psu.edu/).

eQTL Analysis

TCGA breast cancer (BRCA) dataset was used to test for an association between genotype and mRNA abundance further adjusted for DNA methylation and somatic copy number profiles. Pre-processed controlled access germline genotype calls (birdseed algorithm) were downloaded from the TCGA data portal. Putative target genes at each of the risk loci were assigned as described above. For SNPs

missing from the Affymetrix SNP6 platform, proxy SNPs were identified using phase 3 data from the 1000 Genomes project ($r^2 > 0.8$, distance limit = 500KB). TCGA BRCA mRNA, DNA methylation and DNA copy number data were downloaded from GDAC (version: 2016_01_28). After excluding data from women of Asian (N=37), African (N=159) or American Indian/Alaska Native (N=1) ethnicity, matched data (including germ-line genotype data) were available for 547 samples; 415 ER+ samples and 95 ER- samples (ER status was unknown for 37 samples). mRNA data was $\log_2$ transformed for eQTL analysis. Statistical association between mRNA abundance levels and genotype groups (AA, AB, BB) was estimated using multivariate linear regression models with one degree of freedom for genotype groups, adjusted for DNA methylation and copy number data. For DNA methylation arrays, methylation levels of the probe with strongest inverse correlation (otherwise minimum correlation coefficient) with its target gene's expression were used as representative methylation levels of the target gene. Analyses for ER+ and ER- subsets were performed separately. P values were adjusted for multiple comparisons using the Benjamini-Hochberg method [54]. eQTL analyses in ER+ samples of genes at chromosome 11q13 were further stratified by copy-number gains using the threshold defined in TCGA[25] ($\log_2$ copy number > 0.3). The variation in copy number within strata was greatly reduced and the eQTL regression models for these additional stratified analyses were as described above, but adjusted for DNA methylation only.

Survival Analysis

The Metabric[30] breast cancer cohort (EGA Study ID: EGAS00000000083) was used for disease-specific survival analysis (DSS). Data were summarized and quantile-normalized from the raw expression files generated by Illumina BeadStudio (R packages: beadarray v2.4.2 and illuminaHuman v3.db_1.12.2). Raw data files of one Metabric sample were not available at the time of our analysis, and were therefore excluded. The most variable probe was used as a representative for the corresponding gene's mRNA abundance levels. A Cox proportional hazards model was used to estimate pair-wise hazard ratios with the lowest expression group treated as baseline. P-values for

pairwise comparison of survival curves were estimated using Wald tests. The overall test of the Null hypothesis that the expression-derived survival curves show no association with patient outcome was tested with Wald tests (1 degree of freedom, P-trend). P values were further adjusted for multiple comparisons using the Benjamini-Hochberg method[54]. Survival analysis was carried out for ER+ and ER- subsets separately.

Data availability

All CHi-C data sets generated as part of this analysis are publicly available at (https://www.ebi.ac.uk/ena) under the accession code PRJEB23968

Processed data can be visualised at bit.ly/CHiC-BC/. Publicly available data sets that were accessed for this analysis are detailed in Supplementary Table 9.

REFERENCES

1. DeSantis, C., Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. *CA Cancer J Clin* **64**, 52-62 (2014).
2. Michailidou, K. *et al.* Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet* **47**, 373-80 (2015).
3. Hindorff, L.A. *et al.* Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A* **106**, 9362-7 (2009).
4. Freedman, M.L. *et al.* Principles for the post-GWAS functional characterization of cancer risk loci. *Nat Genet* **43**, 513-8 (2011).
5. Edwards, S.L., Beesley, J., French, J.D. & Dunning, A.M. Beyond GWASs: illuminating the dark road from association to function. *Am J Hum Genet* **93**, 779-97 (2013).
6. Dryden, N.H. *et al.* Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. *Genome Res* **24**, 1854-68 (2014).
7. van Berkum, N.L. *et al.* Hi-C: a method to study the three-dimensional architecture of genomes. *J Vis Exp* (2010).
8. Ahmed, S. *et al.* Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet* **41**, 585-90 (2009).
9. Antoniou, A.C. *et al.* A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* **42**, 885-92 (2010).
10. Easton, D.F. *et al.* Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* **447**, 1087-93 (2007).
11. Fletcher, O. *et al.* Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. *J Natl Cancer Inst* **103**, 425-35 (2011).
12. Garcia-Closas, M. *et al.* Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet* **45**, 392-8, 398e1-2 (2013).
13. Ghoussaini, M. *et al.* Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nat Genet* **44**, 312-8 (2012).
14. Haiman, C.A. *et al.* A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nat Genet* **43**, 1210-4 (2011).
15. Hunter, D.J. *et al.* A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet* **39**, 870-4 (2007).
16. Stacey, S.N. *et al.* Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet* **39**, 865-9 (2007).
17. Stacey, S.N. *et al.* Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet* **40**, 703-6 (2008).
18. Thomas, G. *et al.* A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet* **41**, 579-84 (2009).
19. Turnbull, C. *et al.* Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet* **42**, 504-7 (2010).
20. Zheng, W. *et al.* Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nat Genet* **41**, 324-8 (2009).
21. Neve, R.M. *et al.* A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**, 515-27 (2006).
22. Khan, A. *et al.* JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Res* (2017).

23. Hein, R. *et al.* Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS One* **7**, e42380 (2012).
24. Rao, S.S. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665-80 (2014).
25. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61-70 (2012).
26. Michailidou, K. *et al.* Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet* **45**, 353-61, 361e1-2 (2013).
27. Ghoussaini, M. *et al.* Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nat Commun* **4**, 4999 (2014).
28. Darabi, H. *et al.* Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). *Sci Rep* **6**, 32512 (2016).
29. Li, Q. *et al.* Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. *Hum Mol Genet* **23**, 5294-302 (2014).
30. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346-52 (2012).
31. Fasching, P.A. *et al.* The role of genetic breast cancer susceptibility variants as prognostic factors. *Hum Mol Genet* **21**, 3926-39 (2012).
32. Nik-Zainal, S. *et al.* Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature* **534**, 47-54 (2016).
33. de Laat, W. & Duboule, D. Topology of mammalian developmental enhancers and their regulatory landscapes. *Nature* **502**, 499-506 (2013).
34. Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. *Nat Genet* **47**, 598-606 (2015).
35. Sanyal, A., Lajoie, B.R., Jain, G. & Dekker, J. The long-range interaction landscape of gene promoters. *Nature* **489**, 109-13 (2012).
36. Schoenfelder, S. *et al.* The pluripotent regulatory circuitry connecting promoters to their long-range interacting elements. *Genome Res* **25**, 582-97 (2015).
37. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57-74 (2012).
38. Javierre, B.M. *et al.* Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters. *Cell* **167**, 1369-1384 e19 (2016).
39. Horne, H.N. *et al.* Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS One* **11**, e0160316 (2016).
40. Guo, X. *et al.* Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiol Biomarkers Prev* **24**, 1680-91 (2015).
41. Ghoussaini, M. *et al.* Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *Am J Hum Genet* **99**, 903-911 (2016).
42. Bojesen, S.E. *et al.* Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet* **45**, 371-84, 384e1-2 (2013).
43. Glubb, D.M. *et al.* Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *Am J Hum Genet* **96**, 5-20 (2015).
44. Dunning, A.M. *et al.* Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet* **48**, 374-86 (2016).
45. Shi, J. *et al.* Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *Int J Cancer* **139**, 1303-17 (2016).

46. Orr, N. *et al.* Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Hum Mol Genet* **24**, 2966-84 (2015).
47. Meyer, K.B. *et al.* Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *Am J Hum Genet* **93**, 1046-60 (2013).
48. French, J.D. *et al.* Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *Am J Hum Genet* **92**, 489-503 (2013).
49. Zeng, C. *et al.* Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Res* **18**, 64 (2016).
50. Udler, M.S. *et al.* Fine scale mapping of the breast cancer 16q12 locus. *Hum Mol Genet* **19**, 2507-15 (2010).
51. Lawrenson, K. *et al.* Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun* **7**, 12675 (2016).
52. Belton, J.M. *et al.* Hi-C: a comprehensive technique to capture the conformation of genomes. *Methods* **58**, 268-76 (2012).
53. Wingett, S. *et al.* HiCUP: pipeline for mapping and processing Hi-C data. *F1000Res* **4**, 1310 (2015).
54. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. *Behav Brain Res* **125**, 279-84 (2001).

URLs

WashU Epigenome Browser: http://epigenomegateway.wustl.edu/browser/

ENCODE: https://www.encodeproject.org/

ACKNOWLEDGMENTS

We thank Prof Georgia Chenevix-Trench for providing Bre80-Q-TERT cells. This work was supported by Breast Cancer Now and Cancer Research UK. We acknowledge National Health Service funding to the NIHR Royal Marsden Biomedical Research Centre. FD and OCL are additionally supported by the MRC (K006215) and the European Union's Horizon 2020 research and innovation programme under grant agreement No 634570 (FORECEE).

AUTHOR CONTRIBUTIONS

OF, JSB, NHD, NO, FD and SH were responsible for the overall design of the study. JSB, NHD, NJ, VF, NS, LAM, IA and KF were responsible for data generation. Bioinformatics analyses were carried out

683 by SM, SA, SWW, RC, AGR and SH. OCL, FD, SH and OF were responsible for the statistical analyses.

684 JSB, OF and SH wrote the manuscript with input from all authors.

Table 1: Characteristics of 51 informative risk loci in six cell lines

Cell line	T-47D	ZR-75-1	Bre80[1]	BT-20	MDA-MB-231	GM06990[2]
Origin	Breast	Breast	Breast	Breast	Breast	Lymphoblastoid
Cancer/normal	Cancer	Cancer	Normal	Cancer	Cancer	Normal
Receptor status	ER+	ER+	ER-	ER-	ER-	ER-
Breast cancer subtype	Luminal	Luminal	Normal	Basal A	Basal B	N/A
Informative loci (%)	34 (66.7)	38 (74.5)	41 (80.4)	21 (41.2)	27 (52.9)	23 (45.1)
Median peaks per locus (range)	7 (0 - 1,107)	9 (0 – 1,744)	10 (0 – 181)	0 (0 – 246)	1 (0 – 466)	0 (0 – 155)
Median distance between interacting fragments[3] (kb)	1392	1647	349	338	388	534
Number (%) of peaks > 2000 kb	1453 (35.4)	1417 (36.4)	94 (7.3)	128 (9.7)	108 (8.0)	102 (12.5)

[1]Bre80-Q-TERT (Bre80) are normal Bre80 TERT-immortalised mammary epithelial cells, kindly provided by Prof Georgia Chenevix-Trench (Queensland Institute of Medical Research, Brisbane, Queensland, Australia). [2]GM06990 are Epstein-Barr virus transformed B-lymphocytes from the Coriell Cell Repositories (Coriell Institute for Medical Research, New Jersey, USA). [3]Range is not given as it was pre-defined to be 10kb to 5Mb.

Table 2: Risk loci which formed interaction peaks directly (N=33), or via an adjacent risk locus (N=3), with 110 target genes.

Locus	SNP(s)	CHi-C target genes	Nearest gene	Agrees
1p36.22	rs616488	*APITD1; DFFA,* ***PEX14;*** *PGD*	*PEX14*	√+
1p13.2	rs11552449	*OLFML3*; *HIPK1*	*DCLREB1*	X
2q31.1	rs2016394	*CDCA7*; ***DLX2;*** *DYNC1I2*	*DLX2*	√+
2q31.1	rs1550623	***CDCA7***; *DLX2*	*CDCA7*	√+
2q35	rs13387042	*IGFBP5*	*LINC01921, TNP1*	X
2q35	rs16857609	*IGFBP5*; *RPL37A*	*DIRC3, TNS1*	X
3p26.1	rs6762644	*BHLHE40*; *CAV3*; *LINC00312*; *LMCD1*; *c3orf32*; *RAD18*; *SETD5*	*ITPR1*	X
3p24.1	rs4973768	*NGLY1, OXSM*; ***SLC4A7***	*SLC4A7*	√+
4q24	rs9790517	*CENPE*; *PPA2*; ***TET2***	*TET2*	√+
5q11.2	rs889312	***MAP3K1***	*MAP3K1*	√
6p23	rs204247	***RANBP9***	*RANBP9*	√
6q25.1	rs12662670, rs2046210	*ESR1*	*CCDC170*	X
8q21.11	rs6472903	***HNF4G****/PEX2* (adj)	*CASC9, HNF4G*	√+
8q21.11	rs2943559	***HNF4G***; *PEX2*;	*HNF4G*	√+
8q24.21	rs13281615	*CCDC26*; *CASC11,* ***MYC***	*CASC8, CASC21, POU5F1B, MYC*	√+
8q24.21	rs11780156	*CCDC26*; *CASC11,* ***MYC***	*PVT1, MYC*	√+
9p21.3	rs1011970	*CDKN2A*; ***CDKN2B***; *MTAP*	*CDKN2B*	√+
9q31.2	rs10759243	***KLF4*** (adj)	*KLF4*	√

9q31.2	rs865686	***KLF4***	*KLF4*	√
10p12.31	rs7072776, rs11814448	*BMI1*; *COMMD3*; *LOC100499489*; *MIR1915, c10orf114*; ***MLLT10***; *c10orf140*	*DNAJC1, MLLT10*	√+
10q22.3	rs704010	***ZMIZ1***	*ZMIZ1*	√
10q26.13	rs2981579	***FGFR2***	*FGFR2*	√
11p15.5	rs3817198	*FAM99B, KRTAP5-6*; *IGF2*; *KRTAP5-5*; *MRPL23, SNORD131*; *TNNT3*; ***LSP1***, *LINC01150*.	*LSP1*	√+
11q13.1	rs3903072	*DKFZp761E198, MIR1234, OVOL1*; *C11orf68, DRAP1*; *CCDC85B*; *CFL1*; *CTSW, FIBP*; *FOSL1*; *KAT5*; *MUS81, EFEMP2*; *RNASEH2C*; *SART1*; ***SNX32***; *TSGA10IP*; *CCND1*, *FADD*	*SNX32*	√+
11q13.3	rs554219, rs78540526, rs75915166	***CCND1***; ***LINC01488***; *ORAOV1*; *FADD*; *LOC338694*; *MIR3164*; *MRGPRF*; *MRPL21, IGHMBP2*; *MYEOV*; *TPCN2*	*LINC01488, CCND1*	√+
12q24.21	rs1292011	***TBX3***	*TBX3*	√
13q13.1	rs11571833	*PDS5B*	*BRCA2*	X
14q13.3	rs2236007	***PAX9***	*PAX9*	√
14q24.1	rs2588809	*ZFP36L1*	*RAD51B*	X
14q24.1	rs999737	*ZFP36L1*(adj)	*RAD51B*	X
16q12.2	rs17817449, rs11075995	*CRNDE, IRX5*; *IRX3*; *LINC02169*	*FTO*	X
17q22	rs6504950	***STXBP4,*** *COX11*; *TOM1L1*	*STXBP4*	√+
19p13.1	rs8170, rs2363956	*ANO8, GTPBP3*; *DDA1*; *MRPL34*; *NR2F6* ; *USE1, OCEL1*	*BABAM1, ANKLE1*	X
19p13.11	rs4808801	*LRRC25*; *SSBP4, ISYNA1*; *LSM4*; *MRPL34*; *PGPEP1, GDF15, MIR3189*; *UPF1*	*ELL*	X
19q13.31	rs3760982	***KCNN4***	*KCNN4*	√
22q13.1	rs6001930	*LOC101927257*	*MLK1*	X

Where TSS for two or more target genes map to a single HindIII fragment, the genes are separated by a comma. Non-coding RNAs (long non-coding RNAs, microRNAs and small nucleolar RNAs) are indicated in green. There were three loci at which the target gene is assigned indirectly on the basis of interaction peaks with an adjacent locus; these are indicated by (adj). Defining nearest gene; for SNPs that map within a gene (UTR, exons or introns) this gene is considered to be the nearest gene, for SNPs that do not map within a gene, nearest gene is assigned based on the location of the nearest TSS according to RefSeq genes (GRCh37/hg19). Where the nearest gene is a non-coding RNA, the nearest protein-coding gene is also given. CHi-C target genes that are also the nearest gene are indicated in bold. CHi-C targets and the nearest gene are compared in the "Agrees" column; √ = CHi-C data were consistent with the nearest gene being the sole target gene, √+ = CHi-C data were consistent with the nearest gene being one of several target genes, X = CHi-C data support a gene other than the nearest gene as a target.

Table 3: Nine CHi-C putative target genes that were statistically significant eQTLs (FDR adjusted P < 0.1)

Cytoband	SNP	Proxy	Gene		All cancers		ER+ cancers		ER- cancers	
			Nearest	CHi-C target	P	P_{adj}	P	P_{adj}	P	P_{adj}
2q31.1	rs1550623		*CDCA7*	***CDCA7***	0.007	0.087	0.511	0.666	0.330	0.892
11q13.1	rs3903072		*SNX32*	*CTSW*	0.006	0.087	0.064	0.326	0.001	0.101
11q13.1	rs3903072		*SNX32*	***SNX32***	0.007	0.087	0.032	0.268	0.036	0.506
14q13.3	rs2236007	rs1018464	*PAX9*	***PAX9***	0.003	0.066	0.054	0.317	0.248	0.854
14q24.1	rs2588809		*RAD51B*	*ZFP36L1*	0.079	0.380	0.004	0.091	0.256	0.854
17q22	rs6504950	rs9902718	*STXBP4*	*COX11*	0.002	0.059	0.001	0.032	0.403	0.892
19p13.11	rs8170	rs34084277	*BABAM1, ANKLE1**	*MRPL34*	0.001	0.059	0.011	0.173	0.131	0.829
19p13.11	rs4808801		*ELL**	*LRRC25*	0.009	0.092	0.004	0.091	0.768	0.954
19p13.11	rs4808801		*ELL**	*SSBP4*	0.002	0.059	0.0002	0.016	0.475	0.892

* in an analysis that included all genes that are nearest genes, regardless of whether they were also a CHi-C target gene, rs4808801 was also associated with expression of *ELL* (FDR adjusted P = 0.05 for all cancers and P = 0.04 for ER+ cancers) and rs8170 was also associated with expression of *ANKLE1* (FDR corrected P = 0.05 for all cancers).
P = P value (1df *t*-test) per allele association with gene expression, adjusted for methylation and copy number; P_{adj} = P value further adjusted for multiple testing

Table 4: Six CHi-C putative target genes for which there was orthogonal support for at least two additional data sources

Locus	SNP	Gene	eQTL P_{all}	eQTL P_{ER+}	DSS P_{ER+}	727 cancer genes source
2q31.1	rs1550623	*CDCA7*	0.007 (0.09)	0.51 (0.67)	4×10^{-7}	
11q13.1	rs3903072	*FADD*	0.04 (0.28)	0.01* (0.17)	0.0009	cancer related genes panel
12q24.21	rs1292011	*TBX3*	0.28 (0.50)	0.21 (0.52)	0.012	cancer gene census
14q13.3	rs2236007	*PAX9*	0.003 (0.07)	0.05 (0.32)	0.20	cancer related genes panel
14q24.1	rs2588809	*ZFP36L1*	0.08 (0.38)	0.004 (0.09)	0.09	identified in Nik-Zainal et al 2016
19p13.11	rs8170	*MRPL34*	0.001 (0.06)	0.01 (0.17)	0.004	

eQTL P values in parenthesis are FDR adjusted; *excluding 119 ER+ cancers with copy-number gains at *FADD*, P = 0.004